Oculis Holding AG (OCS)
12.96
-0.22
(-1.67%)
USD |
NASDAQ |
Aug 25, 16:00
12.94
-0.02
(-0.12%)
After-Hours: 19:59
Oculis Enterprise Value : 520.15M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 520.15M |
| August 24, 2026 | 533.73M |
| August 21, 2026 | 527.86M |
| August 20, 2026 | 531.26M |
| August 19, 2026 | 557.80M |
| August 18, 2026 | 534.35M |
| August 17, 2026 | 531.26M |
| August 14, 2026 | 518.91M |
| August 13, 2026 | 511.51M |
| August 12, 2026 | 515.83M |
| August 11, 2026 | 507.18M |
| August 10, 2026 | 507.80M |
| August 07, 2026 | 502.86M |
| August 06, 2026 | 484.34M |
| August 05, 2026 | 465.21M |
| August 04, 2026 | 460.27M |
| August 03, 2026 | 454.10M |
| July 31, 2026 | 418.29M |
| July 30, 2026 | 412.12M |
| July 29, 2026 | 389.28M |
| July 28, 2026 | 402.55M |
| July 27, 2026 | 400.39M |
| July 24, 2026 | 407.18M |
| July 23, 2026 | 426.32M |
| July 22, 2026 | 425.70M |
| Date | Value |
|---|---|
| July 21, 2026 | 458.42M |
| July 20, 2026 | 444.22M |
| July 17, 2026 | 472.61M |
| July 16, 2026 | 498.54M |
| July 15, 2026 | 530.03M |
| July 14, 2026 | 518.30M |
| July 13, 2026 | 531.88M |
| July 10, 2026 | 561.51M |
| July 09, 2026 | 565.83M |
| July 08, 2026 | 565.83M |
| July 07, 2026 | 557.19M |
| July 06, 2026 | 572.00M |
| July 02, 2026 | 591.76M |
| July 01, 2026 | 555.34M |
| June 30, 2026 | 576.32M |
| June 29, 2026 | 516.96M |
| June 26, 2026 | 451.14M |
| June 25, 2026 | 435.44M |
| June 24, 2026 | 424.57M |
| June 23, 2026 | 434.23M |
| June 22, 2026 | 431.21M |
| June 18, 2026 | 404.04M |
| June 17, 2026 | 408.87M |
| June 16, 2026 | 417.92M |
| June 15, 2026 | 427.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novartis AG | 334.58B |
| Roche Holding AG | -- |
| Addex Therapeutics Ltd. | 2.841M |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.61M |
| Total Expenses (Quarterly) | 12.61M |
| EPS Diluted (Quarterly) | -0.2059 |
| Earnings Yield | -13.57% |
| Normalized Earnings Yield | -13.99 |